(571) 447-5500

EAS Blog

EAS Independent Consultants and staff provide in-depth regulatory expertise and authoritative reporting on a variety of compliance requirements for industries that EAS serves. Our experts break down complicated topics into easily understandable summaries and analysis. Subscribe to our newsletter and receive these monthly updates directly in your in-box.

Understanding FDA Registrations and the Role of Your US Agent

Understanding FDA Registrations and the Role of Your US Agent

Foreign entities who operate in US FDA-regulated industries must have an appointed FDA US agent before they can import products into the US. At a minimum these FDA US agents provide the most basic of required services. However, agents with relevant experience and knowledge can provide much more.

read more
Drug and Device Corner 2026 October

Drug and Device Corner 2026 October

REMINDER: The drug and medical device establishment registration renewal and listing certification period is underway. Private Label Distributors that manage their own NDC listing submissions should be aware of the listing certification process. Deadline is 31 December 2026. Contact EAS if you...

read more
Celebrating 20 Years of EAS Consulting Group

Celebrating 20 Years of EAS Consulting Group

By Dean Cirotta, EAS Consulting Group PresidentI would like to take the opportunity to use this month’s feature article to celebrate the 20th Anniversary of the founding of EAS Consulting Group. EAS’s beginnings can be traced back to the 1960s, however our current firm began in 2006, when our...

read more
Drug and Device Corner 2026 September

Drug and Device Corner 2026 September

NDC format change is coming. Although there is a seven-year delayed implementation, time does fly. Six months have already passed since announcement of this regulation on 5 March 2026. If you have not yet begun to discuss internally how these changes will be managed, now would be a good time to...

read more
Summary of FDA’s 2026 Proposed Rule on GRAS Substances

Summary of FDA’s 2026 Proposed Rule on GRAS Substances

By Tim Lombardo, Senior Director for Food Consulting ServicesThe FDA’s 2026 Proposed Rule would make GRAS notifications mandatory for human food, animal feed, and food contact substances—transforming what has long been a voluntary system into a required disclosure framework. Companies could still...

read more
Drug and Device Corner 2026 August

Drug and Device Corner 2026 August

FDA has announced the OMUFA facility user fee amounts for FY2027 in the Federal Register Vol 91, No. 145 Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027. Please note the change in due date from previous years. FY2027 marks the transition to aligning the OMUFA facility user fee...

read more
Dietary Supplement Testing and Specifications Seminar

Dietary Supplement Testing and Specifications Seminar

Presented by Shelly BlackwellOctober 21, 2026 | 1:00 PM – 5:00 PM ETSpecifications and testing remain among the most frequently cited deficiencies during FDA inspections of dietary supplement manufacturers. While the requirements of 21 CFR Part 111 have been in place for years, many firms continue...

read more
FDA’s Proposed GRAS Rule Clears White House Review

FDA’s Proposed GRAS Rule Clears White House Review

OMB review is one of the final procedural steps before publication of a proposed federal regulation. As FDA moves forward with its proposed GRAS rule, industry stakeholders should carefully review the proposal once released and evaluate any potential implications for their regulatory and product development activities.

read more
FDA Announces FY2027 FSMA User Fees for VQIP and TPP

FDA Announces FY2027 FSMA User Fees for VQIP and TPP

FDA Releases FY2027 User Fee Information The U.S. Food and Drug Administration (FDA) has announced the Fiscal Year 2027 user fee rates for two voluntary programs established under the Food Safety Modernization Act (FSMA): Voluntary Qualified Importer Program (VQIP) Accredited Third-Party...

read more
Drug and Device Corner 2026 July

Drug and Device Corner 2026 July

Highlighted Guidance Documents Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs The Food and Drug Administration is announcing the availability of a final guidance for industry titled “Formal Meetings Between FDA and Sponsors...

read more
California Food Date Labeling Requirements Take Effect July 1

California Food Date Labeling Requirements Take Effect July 1

California Standardizes Food Date Labels Beginning July 1 Beginning July 1, 2026, food manufacturers, processors, and retailers selling products in California must comply with California's food date labeling law, Assembly Bill 660 (AB 660). The law establishes standardized terminology for food...

read more
USDA Food Safety and Inspection Service (FSIS) Label “Approval Process”

USDA Food Safety and Inspection Service (FSIS) Label “Approval Process”

USDA Food Safety and Inspection Service (FSIS) labels play a critical role in product compliance and market access. This article explores the FSIS label approval process, including generic, sketch, and temporary approvals, while highlighting common compliance challenges and the recordkeeping requirements establishments must maintain to support approved labeling claims.

read more
FDA Updates 2026 Human Foods Program Guidance Agenda

FDA Updates 2026 Human Foods Program Guidance Agenda

FDA Releases Updated 2026 Human Foods Program Guidance Agenda The U.S. Food and Drug Administration has released an updated version of its 2026 Human Foods Program (HFP) Guidance Agenda, adding three new guidance topics for industry consideration. The Human Foods Program Guidance Agenda provides...

read more

Subscribe to the EASeNews Newsletter: